Results of a Meta-Analysis on Intravitreal anti-VEGF Treatment of Macular Oedema Secondary to Branch Retinal Vein Occlusion (BRVO)

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Klinische Monatsblätter für Augenheilkunde

• Publication date

  2017-02-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1055/s-0042-123025PMID 28192843
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intravitreal anti-VEGF Treatment in Central Retinal Vein Occlusion (CRVO): a Meta-Analysis of One Year Results

  2017cited by this paper
• Long-term Results of Intravitreal Anti-VEGF Injections in Wet AMD: A Meta-Analysis

  2016cited by this paper
• Individualized Stabilization Criteria-Driven Ranibizumab versus Laser in Branch Retinal Vein Occlusion: Six-Month Results of BRIGHTER.

  2016cited by this paper
• Individualized Ranibizumab Regimen Driven by Stabilization Criteria for Central Retinal Vein Occlusion: Twelve-Month Results of the CRYSTAL Study.

  2016cited by this paper
• Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study.

  2016cited by this paper
• A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL Report No. 1

  2015cited by this paper
• Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study.

  2015cited by this paper
• Comparison of intravitreal bevacizumab and dexamethasone implant for the treatment of macula oedema associated with branch retinal vein occlusion

  2015cited by this paper
• Strategy for the Management of Macular Edema in Retinal Vein Occlusion: The European VitreoRetinal Society Macular Edema Study

  2015cited by this paper
• Scatter Photocoagulation Does Not Reduce Macular Edema or Treatment Burden in Patients with Retinal Vein Occlusion: The RELATE Trial.

  2015cited by this paper
• Treatment of Retinal Vein Occlusion with Ranibizumab in Clinical Practice: Longer-Term Results and Predictive Factors of Functional Outcome

  2015cited by this paper
• Ranibizumab Treatment in Age-Related Macular Degeneration: A Meta-Analysis of One-Year Results

  2014cited by this paper
• INTRAVITREAL RANIBIZUMAB FOR RETINAL VEIN OCCLUSION THROUGH 1 YEAR IN CLINICAL PRACTICE

  2014cited by this paper
• Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study.

  2014cited by this paper
• Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion.

  2014cited by this paper
• Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel

  2014cited by this paper
• Treat-and-extend intravitreal bevacizumab for branch retinal vein occlusion.

  2014cited by this paper
• Initial Dose of Three Monthly Intravitreal Injections versus PRN Intravitreal Injections of Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion

  2013cited by this paper
• Two-year outcomes of intravitreal bevacizumab therapy for macular oedema secondary to branch retinal vein occlusion

  2013cited by this paper
• Comparison of Natural Course, Intravitreal Triamcinolone, and Intravitreal Bevacizumab for Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion

  2013cited by this paper
• Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion

  2013cited by this paper
• RESPONSE OF RETINAL SENSITIVITY TO RANIBIZUMAB TREATMENT OF MACULAR EDEMA AFTER ACUTE BRANCH RETINAL VEIN OCCLUSION

  2013cited by this paper
• THREE TREATMENTS FOR MACULAR EDEMA BECAUSE OF BRANCH RETINAL VEIN OCCLUSION: Intravitreous Bevacizumab or Tissue Plasminogen Activator, and Vitrectomy

  2012cited by this paper
• 25-gauge vitrectomy versus intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion: 1 year follow-up.

  2012cited by this paper
• Intravitreous Bevacizumab Treatment for Macular Edema due to Central Retinal Vein Occlusion

  2012cited by this paper
• Intravitreal Bevacizumab Treatment for Macular Edema due to Branch Retinal Vein Occlusion in a Clinical Setting

  2012cited by this paper
• Results of flexible ranibizumab treatment in age-related macular degeneration and search for parameters with impact on outcome

  2011cited by this paper
• Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study.

  2011cited by this paper
• Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study.

  2011cited by this paper
• Intravitreal Ranibizumab for Macular Edema Secondary to Retinal Vein Occlusion

  2011cited by this paper
• Antagonism of Vascular Endothelial Growth Factor for Macular Edema Caused by Retinal Vein Occlusions: Two-Year Outcomes

  2011cited by this paper
• Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.

  2010cited by this paper
• The effect of a preoperative subconjuntival injection of dexamethasone on blood–retinal barrier breakdown following scleral buckling retinal detachment surgery: a prospective randomized placebo-controlled double blind clinical trial

  2010cited by this paper
• Intravitreal triamcinolone acetonide versus bevacizumab therapy for macular edema associated with branch retinal vein occlusion

  2010cited by this paper
• Results of bevacizumab as the primary treatment for retinal vein occlusions

  2010cited by this paper
• Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: two-year outcomes.

  2010cited by this paper
• Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.

  2010cited by this paper
• Ranibizumab for macular edema following branch retinal vein occlusion

  2010cited by this paper
• Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion

  2010cited by this paper
• Intravitreal Injection of Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion

  2010cited by this paper
• COMPARISON OF TWO DOSES OF INTRAVITREAL BEVACIZUMAB AS PRIMARY TREATMENT FOR MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSIONS: Results of the Pan American Collaborative Retina Study Group at 24 Months

  2009cited by this paper
• SAFETY AND EFFICACY OF INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR THE MANAGEMENT OF BRANCH AND HEMIRETINAL VEIN OCCLUSION

  2009cited by this paper
• BEVACIZUMAB COMPARED WITH MACULAR LASER GRID PHOTOCOAGULATION FOR CYSTOID MACULAR EDEMA IN BRANCH RETINAL VEIN OCCLUSION

  2009cited by this paper
• INTRAVITREAL INJECTION OF BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION: Results After 12 Months and Multiple Regression Analysis

  2009cited by this paper
• One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion

  2008cited by this paper
• Early Intravitreal Bevacizumab for Non-Ischaemic Branch Retinal Vein Occlusion

  2008cited by this paper
• Natural history of macular status in recent-onset branch retinal vein occlusion: an optical coherence tomography study

  2008cited by this paper
• Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion

  2008cited by this paper
• Results of the

  1975cited by this paper

• Theme trends in research related to retinal vein occlusion: a quantitative and co-word analysis

  2019influential citation
• Intravitreal dexamethasone implants versus intravitreal anti-VEGF treatment in treating patients with retinal vein occlusion: a meta-analysis

  2018cites this paper
• Intravitreal anti-VEGF Treatment in Central Retinal Vein Occlusion (CRVO): a Meta-Analysis of One Year Results

  2017cites this paper